A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric Blood & Cancer.

We conducted a phase 1b–2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A ...